Clinical trials: Paramyotonia Congenita
Paralysis, Hyperkalemic Periodic, Hypokalemic Periodic Paralysis
Phase III Randomized, Double-Blind, Placebo-Controlled Study of Dichlorphenamide for Periodic Paralyses and Associated Sodium Channel Disorders
OBJECTIVES: I. Assess the efficacy of dichlorphenamide in the treatment of episodic weakness attacks in patients with hyperkalemic periodic paralysis, paramyotonia congenita with periodic paralysis, and hypokalemic periodic…
- Conditions
- Paralysis, Hyperkalemic Periodic, Hypokalemic Periodic Paralysis, Paramyotonia Congenita
- Trial name
- NCT00004802
- Testing
- dichlorphenamide
- Volunteers
- 64 people
- Sponsor
- National Center for Research Resources (NCRR)
Paramyotonia Congenita, Nondystrophic Myotonia
Using MRI in Patients With Non-dystrophic Myotonia to Access Muscle Contractility
The aim of this project is (1) to investigate whether or not structural muscle abnormalities could be a consequence of the disorder and (2) to provide further clinical description of this rare phenotype.
- Trial name
- NCT04808388
- Testing
- MRI
- Where
- Denmark
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Non Dystrophic Myotonia
Combined N-of-1 Trials Mexiletine vs Placebo in Patients With Non-Dystrophic Myotonia (NDM)
The main objective of this study is to explore whether multiple trials with individual patients (N-of-1 trials) can produce a reliable evidence base for coverage decisions on clinical and cost-effectiveness of drug treatment for…
- Trial name
- NCT02045667
- Testing
- Mexiletine
- Where
- Netherlands
- Volunteers
- 30 people
- Sponsor
- Radboud University Medical Center
Nondystrophic Myotonias, Myotonia Congenita
Characteristics of Nondystrophic Myotonias
Nondystrophic myotonias (NDM) are muscle disorders caused by genetic abnormalities in certain muscle cell membrane proteins. Individuals with NDM experience limited muscle relaxation, which causes pain, weakness, and impaired…
- Conditions
- Nondystrophic Myotonias, Myotonia Congenita, Myotonic Disorders
- Trial name
- NCT00244413
- Where
- 6 sites in United States, Canada and 1 more
- Volunteers
- 94 people
- Sponsor
- Richard Barohn, MD
Myotonia Congenita, Paramyotonia Congenita
Study of Ranolazine in Myotonia Congenita, Paramyotonia Congenita and Myotonic Dystrophy Type 1
The purpose of this study is to gather preliminary data to determine if ranolazine is a safe and effective treatment for the symptoms of myotonia congenital, paramyotonia congenita, and myotonic dystrophy type 1.
- Conditions
- Myotonia Congenita, Paramyotonia Congenita, Myotonic Dystrophy 1
- Trial name
- NCT02251457
- Testing
- Ranolazine
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Ohio State University
Non-dystrophic Myotonias, Paramyotonia Congenita
Mexiletine and Non Dystrophic Myotonias
Treatment strategies in non-dystrophic myotonias are based on selective case reports, clinical experience and theoretical benefit.
- Conditions
- Non-dystrophic Myotonias, Paramyotonia Congenita, Myotonia Congenita
- Trial name
- MYOMEX (NCT02336477)
- Testing
- Mexiletine
- Where
- France
- Volunteers
- 24 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Non-Dystrophic Myotonia
Treatment of Myotonia - Lamotrigine Versus Namuscla
In this clinical study, the aim is to investigate whether there is a difference in treatment of myotonia using two drugs. A difference there can justify the significantly higher cost when treated by Namuscla versus Lamotrigine.
- Trial name
- NCT05639257
- Testing
- Lamotrigine, Namuscla
- Where
- Denmark
- Volunteers
- 32 people
- Sponsor
- Grete Andersen, MD
Dystrophia Myotonica Type 1, Myotonia Congenita
Lamotrigine as Treatment of Myotonia
Myotonia is a functional limiting symptom where the muscle stiffens on action leading to arrest of movement. Pharmacological treatment may make the difference between a physically restricted and a normal life.
- Conditions
- Dystrophia Myotonica Type 1, Myotonia Congenita, Paramyotonia Congenita, Hyperkalemic Periodic Paralysis
- Trial name
- NCT01939561
- Testing
- Lamotrigine
- Where
- Denmark
- Volunteers
- 27 people
- Sponsor
- Grete Andersen, MD